Tango Therapeutics (NASDAQ:TNGX – Get Free Report) and ImageneBio (NASDAQ:IMA – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, risk, institutional ownership, earnings, dividends and analyst recommendations.
Analyst Recommendations
This is a summary of current ratings and target prices for Tango Therapeutics and ImageneBio, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tango Therapeutics | 2 | 2 | 13 | 0 | 2.65 |
| ImageneBio | 2 | 0 | 0 | 1 | 2.00 |
Tango Therapeutics presently has a consensus target price of $48.17, suggesting a potential upside of 123.87%. ImageneBio has a consensus target price of $28.00, suggesting a potential upside of 629.17%. Given ImageneBio’s higher probable upside, analysts clearly believe ImageneBio is more favorable than Tango Therapeutics.
Insider and Institutional Ownership
79.0% of Tango Therapeutics shares are owned by institutional investors. Comparatively, 75.0% of ImageneBio shares are owned by institutional investors. 6.5% of Tango Therapeutics shares are owned by insiders. Comparatively, 2.2% of ImageneBio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Volatility & Risk
Tango Therapeutics has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500. Comparatively, ImageneBio has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500.
Profitability
This table compares Tango Therapeutics and ImageneBio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tango Therapeutics | N/A | -30.34% | -28.28% |
| ImageneBio | N/A | -32.90% | -29.66% |
Valuation & Earnings
This table compares Tango Therapeutics and ImageneBio”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Tango Therapeutics | $62.38 million | 58.45 | -$101.59 million | ($1.37) | -15.70 |
| ImageneBio | $800,000.00 | 59.81 | -$45.35 million | ($4.58) | -0.84 |
ImageneBio has lower revenue, but higher earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.
Summary
Tango Therapeutics beats ImageneBio on 9 of the 14 factors compared between the two stocks.
About Tango Therapeutics
Tango Therapeutics is a biotechnology company focused on discovering and developing precision medicines for cancer. Based in Cambridge, Massachusetts, the company aims to develop treatments that exploit genetic differences between cancer cells and healthy cells. Its research centers on synthetic lethality, an approach that seeks to identify vulnerabilities created when cancer cells lose or alter particular genes. Tango uses this strategy to find drug targets and develop investigational therapies for tumors with specific genetic alterations.
About ImageneBio
ImageneBio, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for immune-mediated and inflammatory diseases. Its research and development pipeline includes investigational medicines at various stages of clinical development; the company does not yet have marketed products. Key programs include IMG-007, an investigational antibody targeting OX40 being studied for atopic dermatitis and other inflammatory conditions, and IMG-004, an oral investigational BTK inhibitor for immune-mediated diseases.
Receive News & Ratings for Tango Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tango Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
